AC
EVFM

Aristides Capital’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Aristides Capital’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,144
Closed -$222K – 193
2020
Q4 		$222K Buy
+6,144
New +$222K 0.08% 102

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
GLA
Great Lakes Advisors Chicago, Illinois $12.1B AUM 29.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aristides Capital's EVFM Position: Q1 2021 in Review

Aristides Capital sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q1 2021, closing a stake of 6,144 shares — an estimated $222K sold.

Aristides Capital first reported a position in EVFM in Q4 2020 and held it in 1 quarter. The position peaked at $222K in Q4 2020. 103 funds tracked by Wall St. Rank hold EVFM as of Q1 2021.

  • Aristides Capital reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Aristides Capital sold 6,144 Evofem Biosciences, Inc. Common Stock shares in Q1 2021, an estimated $222K.
  • Aristides Capital first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Aristides Capital's Evofem Biosciences, Inc. Common Stock position peaked at $222K in Q4 2020.
  • 103 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q1 2021.

Based on Aristides Capital's 13F filing for Q1 2021, filed 17 May 2021.